10146161DPN-MED: Digital Plug-and-Produce Network for Sustainable Medicines Development and ManufacturingClosedFeasibility StudiesInnovate UKThe pharmaceutical industry is a major contributor to global greenhouse gas (GHG) emissions, with the UK healthcare sector accounting for 5% of the nation's total emissions, 20% of which are linked to medicines. Pharmaceutical emissions are 55% higher than those of the automotive industry, generating up to 100 kg of waste per kg of product. This carbon footprint is expected to increase further due to the rise in smaller production volumes, personalised therapies, and other emerging factors. To tackle this challenge, we need a strong partnership that can make the UK a leader in sustainable, innovative medicines production, benefiting the economy, society, and the environment. The Grand Challenge (GC) aims to transform how medicines are made by shifting from outdated, costly medicine development and manufacturing systems to automated and resource efficient approaches. This new approach will integrate advanced digital tools with medicines development and manufacturing technologies, allowing labs and factories to produce medicines more efficiently and with less waste. One key feature is the creation of a network of self-driving development and manufacturing systems, which can communicate, operate and share information securely in real-time. A cloud-based platform with different services will deliver new ways of data management, sustainability, and regulatory compliance. These tools will realise a step change in how the industry ensures safety, quality, and environmental impact of the medicines we produce. A user-friendly platform will allow companies to use these tools remotely and improve their processes. During the Expression of Interest (EoI) phase, we will work with key stakeholders to develop a detailed plan for this initiative. This will involve working groups that focus on different areas, such as building partnerships, developing use cases, creating digital infrastructure, and promoting sustainability. The goal is to create a roadmap for the future of medicines manufacturing.